title: [Nosocomial fungemias in a general hospital. Epidemiology and prognostic factors. Prospective study 1993-1998].
abstract: BACKGROUND
  Nosocomial fungemias are infections with a high mortality rate. In last years the incidence of these infections has increased probably because of the growing population of immunocompromised patients who undergo aggressive diagnostic and therapeutic techniques.
  
  
  OBJECTIVE
  To know the epidemiologic characteristics, risk factors, clinical features and prognosis of fungemia.
  
  
  METHODS
  We prospectively evaluated all the patients with proven fungemia in our center during a 5 year-period. After finishing antifungal treatment a minimum follow-up of 1 month was carried out. Fungal isolation and identification were performed by standard tests.
  
  
  RESULTS
  During the period of study we evaluated 81 patients with an episode of nosocomial fungemia. Global incidence was 0,9 episodes per thousand admitted patients. Candida albicans was the more frequently isolated species (n=53), followed by C. parapsilosis (n=11), C. tropicalis (n=6) and C. glabrata (n=5). Most of the patients had a central intravenous line and were on parenteral nutrition therapy. All of them previously received at least one course of broad-spectrum antibiotics. Overall mortality was 49,6%. A worst prognosis was significantly associated with: age over 65 years, surgical procedures during present admission, leucocytosis, shock, and delay in antifungal treatment.
  
  
  CONCLUSIONS
  Fungal bloodstream infection incidence is high in our environment. It is associated with a high mortality rate, specially in patients in whom the beginning of antifungal treatment was delayed. A higher clinical suspicion index may improve the poor outcome in these patients.
authors.affiliation: Infecciosas, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Gómez
authors.forename: V
authors.initials: V
authors.lastname: Baños
authors.forename: E
authors.initials: E
authors.lastname: Simarro
authors.forename: J
authors.initials: J
authors.lastname: Ruiz
authors.forename: L
authors.initials: L
authors.lastname: Requena
authors.forename: J
authors.initials: J
authors.lastname: Pérez
authors.forename: M
authors.initials: M
authors.lastname: Canteras
authors.forename: M
authors.initials: M
authors.lastname: Valdés
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000453:epidemiology; D002405:Catheterization, Central Venous / Q000009:adverse effects; D015897:Comorbidity; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010289:Parenteral Nutrition, Total; D011183:Postoperative Complications / Q000453:epidemiology / Q000382:microbiology; D011446:Prospective Studies; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents